May 05, 2011, 05.43 PM IST | Source: Moneycontrol.com

Strides gets US FDA nod for anesthetic drug, Midazolam

Strides Arcolab Thursday said it has got approval from US Food and Drug Adminstrator for its general anesthetic injection, Midazolam in multiple-dose vials.

Strides gets US FDA nod for anesthetic drug, Midazolam

Strides Arcolab Thursday said it has got approval from US Food and Drug Adminstrator for its general anesthetic injection, Midazolam in multiple-dose vials.

The pharmaceutical company has got approval to market Midazolam injection of 1 mg/ml packaged in 10mg/10 ml multiple-dose vials and 5mg/ml packages in 25 mg/5ml and 50 mg/10ml multiple-dose vials.

Midazolam Injection will be launched in the third quarter of 2011-12, in partnership with US-based Sagent Pharmaceuticals and aims to address over 95% of the sterile injectable market for Midazolam in the US.

The total market for Midazolam in the USA is about USD 51 million, according to IMS September 2010 data, the company said in a press release to the stock exchanges.

At 13:50 hrs, shares of Strides Arcolab was trading at Rs 389.35, down 1% on the Bombay Stock Exchange.

Strides Arcolab stock price

On April 17, 2014, Strides Arcolab closed at Rs 453.75, up Rs 0.20, or 0.04 percent. The 52-week high of the share was Rs 1050.00 and the 52-week low was Rs 343.80.


The company's trailing 12-month (TTM) EPS was at Rs 597.86 per share as per the quarter ended December 2013. The stock's price-to-earnings (P/E) ratio was 0.76. The latest book value of the company is Rs 828.22 per share. At current value, the price-to-book value of the company is 0.55.

Set email alert for

ADS BY GOOGLE

Buy & sell politicians on Power Play
- the political stock exchange

Price Update

Rahul Gandhi

574.44 -1.79 -0.31%

37711

Bought today

45493

Sold today

0.16%

User holding

video of the day

Chandra says satisfied with TCS' FY14, FY15 to be better

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.